All In Biotech

Free tool

FAERS Monitor: Vyxeos

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209401 or its brand name (Vyxeos, Cytarabine, Daunorubicin). Reports on generic versions are filed under their own applications.

Reports

2,431

Serious

2,136

88% of reports

Hospitalization

582

Death reported

825

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia528
  • acute myeloid leukaemia313
  • death244
  • therapeutic product effect incomplete217
  • pyrexia206
  • acute myeloid leukaemia recurrent177
  • rash152
  • pneumonia151
  • sepsis142
  • off label use121
  • cytopenia81
  • disease progression80
  • septic shock77
  • drug ineffective76
  • myelosuppression71

Reports by year received

View as table
YearReports
201712
201877
2019231
2020183
2021171
2022346
202374
2024471
2025455
2026411

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,728 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute myeloid leukaemia recurrentSignal177777.3670.0125,221
acute myeloid leukaemiaSignal313177.3159.753,635
febrile neutropeniaSignal52869.464.335,361
cytopeniaSignal8157.646.54,423
therapeutic product effect incompleteSignal21726.523.35,295
myelosuppressionSignal7117.113.61,059
septic shockSignal7715.312.31,018
sepsisSignal14211.09.41,290
disease progressionSignal805.94.7319
pyrexiaSignal2065.24.5696
pneumoniaSignal1514.03.5347
rashSignal1523.02.6207
deathSignal2442.52.2217
off label use1211.21.04
drug ineffective760.50.440

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.